New findings on thymic epithelial tumors: Something is changing

Rossana Berardi, Francesca Morgese, Marina Chiara Garassino, Stefano Cascinu

Research output: Contribution to journalArticle

Abstract

Thymic epithelial tumors (TETs) are uncommon neoplasms with a wide range of anatomical, clinical, histological and molecular malignant entities. To date the management of TETs within clinical practice is based on a multimodal therapeutic strategy including surgery, chemotherapy and radiotherapy with a multidisciplinary approach and prognostic evaluation is mainly based on Masaoka staging and World Health Organization classification. Therefore novel strategies are needed, especially for refractory and/or recurrent TETs and for thymic carcinomas that present a poor prognosis. Personalized approaches are currely being developed and molecular targets are emerging from recent integrated genomic analyses. Targeted therapy will represent an important treatment option for TETs with an aggressive histology. To date, data indicate that vascular endothelial growth factor molecules, insulinlike growth factor 1 receptor, cyclin-dependent kinases and mammalian target of rapamycin may be potentially useful as targeted biological therapies.

Original languageEnglish
Pages (from-to)96-98
Number of pages3
JournalWorld Journal of Clinical Oncology
Volume6
Issue number5
DOIs
Publication statusPublished - Oct 10 2015

Fingerprint

CDC2 Protein Kinase
Biological Therapy
Thymoma
Growth Factor Receptors
Sirolimus
Vascular Endothelial Growth Factor A
Histology
Radiotherapy
Therapeutics
Drug Therapy
Thymic epithelial tumor
Neoplasms

Keywords

  • Programmed cell death-1
  • Targeted therapy
  • Thymic carcinoma
  • Thymic epithelial tumors
  • Thymoma

ASJC Scopus subject areas

  • Oncology

Cite this

New findings on thymic epithelial tumors : Something is changing. / Berardi, Rossana; Morgese, Francesca; Garassino, Marina Chiara; Cascinu, Stefano.

In: World Journal of Clinical Oncology, Vol. 6, No. 5, 10.10.2015, p. 96-98.

Research output: Contribution to journalArticle

Berardi, Rossana ; Morgese, Francesca ; Garassino, Marina Chiara ; Cascinu, Stefano. / New findings on thymic epithelial tumors : Something is changing. In: World Journal of Clinical Oncology. 2015 ; Vol. 6, No. 5. pp. 96-98.
@article{5c5e2d38014f4cb5a78cf9b904d82151,
title = "New findings on thymic epithelial tumors: Something is changing",
abstract = "Thymic epithelial tumors (TETs) are uncommon neoplasms with a wide range of anatomical, clinical, histological and molecular malignant entities. To date the management of TETs within clinical practice is based on a multimodal therapeutic strategy including surgery, chemotherapy and radiotherapy with a multidisciplinary approach and prognostic evaluation is mainly based on Masaoka staging and World Health Organization classification. Therefore novel strategies are needed, especially for refractory and/or recurrent TETs and for thymic carcinomas that present a poor prognosis. Personalized approaches are currely being developed and molecular targets are emerging from recent integrated genomic analyses. Targeted therapy will represent an important treatment option for TETs with an aggressive histology. To date, data indicate that vascular endothelial growth factor molecules, insulinlike growth factor 1 receptor, cyclin-dependent kinases and mammalian target of rapamycin may be potentially useful as targeted biological therapies.",
keywords = "Programmed cell death-1, Targeted therapy, Thymic carcinoma, Thymic epithelial tumors, Thymoma",
author = "Rossana Berardi and Francesca Morgese and Garassino, {Marina Chiara} and Stefano Cascinu",
year = "2015",
month = "10",
day = "10",
doi = "10.5306/wjco.v6.i5.96",
language = "English",
volume = "6",
pages = "96--98",
journal = "World Journal of Clinical Oncology",
issn = "2218-4333",
publisher = "Baishideng Publishing Group",
number = "5",

}

TY - JOUR

T1 - New findings on thymic epithelial tumors

T2 - Something is changing

AU - Berardi, Rossana

AU - Morgese, Francesca

AU - Garassino, Marina Chiara

AU - Cascinu, Stefano

PY - 2015/10/10

Y1 - 2015/10/10

N2 - Thymic epithelial tumors (TETs) are uncommon neoplasms with a wide range of anatomical, clinical, histological and molecular malignant entities. To date the management of TETs within clinical practice is based on a multimodal therapeutic strategy including surgery, chemotherapy and radiotherapy with a multidisciplinary approach and prognostic evaluation is mainly based on Masaoka staging and World Health Organization classification. Therefore novel strategies are needed, especially for refractory and/or recurrent TETs and for thymic carcinomas that present a poor prognosis. Personalized approaches are currely being developed and molecular targets are emerging from recent integrated genomic analyses. Targeted therapy will represent an important treatment option for TETs with an aggressive histology. To date, data indicate that vascular endothelial growth factor molecules, insulinlike growth factor 1 receptor, cyclin-dependent kinases and mammalian target of rapamycin may be potentially useful as targeted biological therapies.

AB - Thymic epithelial tumors (TETs) are uncommon neoplasms with a wide range of anatomical, clinical, histological and molecular malignant entities. To date the management of TETs within clinical practice is based on a multimodal therapeutic strategy including surgery, chemotherapy and radiotherapy with a multidisciplinary approach and prognostic evaluation is mainly based on Masaoka staging and World Health Organization classification. Therefore novel strategies are needed, especially for refractory and/or recurrent TETs and for thymic carcinomas that present a poor prognosis. Personalized approaches are currely being developed and molecular targets are emerging from recent integrated genomic analyses. Targeted therapy will represent an important treatment option for TETs with an aggressive histology. To date, data indicate that vascular endothelial growth factor molecules, insulinlike growth factor 1 receptor, cyclin-dependent kinases and mammalian target of rapamycin may be potentially useful as targeted biological therapies.

KW - Programmed cell death-1

KW - Targeted therapy

KW - Thymic carcinoma

KW - Thymic epithelial tumors

KW - Thymoma

UR - http://www.scopus.com/inward/record.url?scp=84945129886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945129886&partnerID=8YFLogxK

U2 - 10.5306/wjco.v6.i5.96

DO - 10.5306/wjco.v6.i5.96

M3 - Article

AN - SCOPUS:84945129886

VL - 6

SP - 96

EP - 98

JO - World Journal of Clinical Oncology

JF - World Journal of Clinical Oncology

SN - 2218-4333

IS - 5

ER -